503A vs 503B Pharmacy: What Your Practice Can Stock

By Portrait Editorial · Medically reviewed by Patrick Blake, MD, FAAD · Last updated 2026-09-04

If you're comparing a 503A vs 503B pharmacy for your practice, the useful question is not which label sounds better. It is what you plan to do with the compounded product after it arrives.

In simple terms:

• 503A pharmacy: Generally prepares compounded medication for an identified patient based on a patient-specific prescription.
• 503B outsourcing facility: Generally prepares certain compounded medications in larger quantities without patient-specific prescriptions, including products intended for office use, subject to applicable requirements.

This guide explains:

1. What 503A and 503B mean
2. Which route generally fits patient-specific dispensing
3. Which route fits office-use stock
4. How to vet a compounding source before ordering

This guide focuses on sourcing and practice operations only, not clinical use or legal advice. Federal requirements and state pharmacy rules both matter, so confirm the current rules for every state where your practice operates.

Note: In this guide, "compounding" refers to preparing a medication by combining, mixing, or altering ingredients to create a particular formulation.

What Is a 503A Pharmacy?

A 503A pharmacy is a pharmacy that prepares drugs under Section 503A of the Federal Food, Drug, and Cosmetic Act. In general, the process starts with a prescription for an identified patient. The pharmacy prepares and dispenses the medication for that patient rather than making a supply of compounded medication for a practice to keep as office stock.

503A pharmacies are primarily regulated by state boards of pharmacy and must meet applicable state requirements. When they satisfy the conditions of Section 503A, they are generally exempt from federal current good manufacturing practice (cGMP) requirements.

This exemption does not mean that every 503A preparation is inherently poorer in quality. It means that 503A pharmacies operate under a different regulatory framework than the one applied to drug manufacturers and 503B outsourcing facilities.

For a practice owner, the key takeaway is simple: 503A is the patient-specific route. Federal law limits compounding for office stock under Section 503A, and state rules may add additional requirements or restrictions.

Do not treat a state pharmacy license as automatic permission to supply bulk office-use inventory.

What Is a 503B Pharmacy?

A 503B outsourcing facility is a facility that has registered with the FDA under Section 503B of the Federal Food, Drug, and Cosmetic Act.

The FDA's formal term is "outsourcing facility." While "503B pharmacy" is sometimes used informally by buyers, a 503B outsourcing facility is not necessarily a pharmacy and is not required to be licensed as one under federal law.

503B outsourcing facilities must follow cGMP requirements and are subject to FDA inspection. They also remain subject to applicable state licensing requirements.

Importantly, FDA registration does not mean that the facility or its compounded products are FDA-approved. Registration means the facility has submitted the required registration information. It does not mean that the FDA has determined the facility is compliant with cGMP requirements or all Section 503B conditions.

For a practice owner, 503B is the office-use stock route. When evaluating a supplier, verify that the specific facility is currently registered with the FDA and that the facility's name and address match the registration and purchasing documentation.

How Does a 503B Outsourcing Facility Differ From a 503A Pharmacy?

The practical difference between the two is the basis for the order.

A 503A pharmacy generally fills a patient-specific prescription. A 503B outsourcing facility may supply eligible compounded stock for administration in a health care setting without a patient-specific prescription in hand.

The 503A or 503B classification changes how a practice can legally obtain and stock a compounded product. It does not change the clinical identity of the product.

Start by determining how your practice needs to hold and use the product, then select a compounding source that is allowed to fill that type of order.

How Does 503A vs 503B Pharmacy Sourcing Work for Office Use?

For 503A vs 503B for office use, identify the product and the intended inventory model before requesting a quote. The answer usually falls into one of three purchasing paths:

• Patient-specific compounded product: Send the prescription for the identified patient to a qualified 503A pharmacy. The pharmacy compounds and dispenses it under the patient-specific model.
• Office-use compounded stock: Evaluate a qualified 503B outsourcing facility. This route allows eligible compounded product to be stocked for administration in the practice without a separate prescription submitted before each unit is made.
• Manufactured drug: Buy through the product's authorized manufacturer or distribution channel. Botox, for example, is a manufactured drug, not a compounded product from a 503A or 503B facility.

This distinction shapes what a practice can legally keep on the shelf. It also prevents a common buying mistake: treating every pharmacy that compounds as interchangeable. A license to dispense patient-specific prescriptions does not by itself establish authority to supply bulk office stock.

The same office-use question can arise when reviewing compounded peptide sourcing. Consider the product-specific federal and state requirements before ordering. Availability through a compounding facility does not mean that a particular ingredient, formulation, or intended use is eligible for compounding.

For IV therapy and NAD+ supply sourcing, confirm whether each item is a manufactured product or a compounded preparation before choosing an ordering path.

Exosome product sourcing requires the same product-level review. Do not assume that one facility registration covers every product it offers.

When buying numbing cream for a medical practice, confirm whether the order is patient-specific or intended as office-use stock.

How to Vet a Compounding Pharmacy or Facility?

A compounding pharmacy or facility for a medical practice should be vetted based on the order you intend to place. Do not stop after confirming that the company calls itself a pharmacy. Also confirm:

• Order model: Ask whether the product is being supplied for an identified patient under a patient-specific prescription or for office-use stock.
• Facility identity: Confirm the legal name of the facility that compounds the product. Do not rely only on the ordering website or sales representative.
• 503B registration: For office-use stock, verify the facility's current registration on the FDA's registered outsourcing facilities list.
• State licensing: Confirm the licenses required for the facility, the practice, and the location where the product will be received. State rules can be more restrictive than federal ones. For prescription products, also review which providers can legally buy injectables.
• Inspection history: Review FDA inspection records, warning letters, recalls, and other public compliance information tied to the facility. Registration alone is not a quality guarantee.
• Product records: Confirm the label, lot number, beyond-use date, storage requirements, invoice source, and process for reporting a product concern.
• Authorized source: A supplier should be willing to identify who compounds, sells, and ships the product.

For a broader purchasing checklist across injectables, compounded products, and clinical supplies, use the medical spa supplies sourcing hub.

If a product's identity or supply path is unclear, review how to spot counterfeit and unauthorized products before ordering.

How Do Compounded Drugs Differ From FDA-Approved Drugs?

Compounded drugs are not FDA-approved drugs. The FDA does not review a compounded product for safety, effectiveness, and quality before it reaches the market in the same way it reviews a manufacturer-approved drug. This distinction applies to products from both 503A pharmacies and 503B outsourcing facilities.

This does not make a compounded drug the same as a counterfeit drug. A compounded drug is prepared under a compounding framework for a clinical need. A counterfeit drug is misrepresented in its identity, source, or authenticity.

Your practice still needs to confirm that the compounder and the order fit the applicable federal and state rules.

503B registration permits a type of compounding and distribution. It does not convert the compounded product into an FDA-approved drug. Keep this distinction clear in your purchasing records, patient communication, and internal inventory controls.

Buying Wholesale Supplies Through Portrait's Marketplace

Portrait's Marketplace gives independent practices a way to source eligible office-use compounded products through license-verified 503B outsourcing facilities where applicable. Practices can review the facility identity, seller, fulfillment path, invoice source, and product documentation alongside their wider supply needs. Across Portrait's Marketplace as a whole, practices can save up to 60% on select products.*

Prices are current as of September 2026 and vary by account, volume, and product mix.

Supply savings are quoted per practice, based on your product mix and volume. Discounts deepen as your membership tier rises.

Portrait also runs its own practices. Every product Portrait lists is one its clinics order from the same catalog, on the same terms offered to members. The sourcing standards, documentation checks, and pricing are the same ones Portrait uses in its own locations.

• National-account pricing: Order eligible office-use products through the same catalog Portrait's clinics use, without needing chain-level volume to reach that pricing.
• Additive to your existing supplier relationships: Keep the supplier relationships you use today. Portrait's Marketplace sits alongside them. It does not ask you to give them up.
• Points on every brand: Marketplace points accrue on everything you source, across every brand in your basket, redeemable monthly.
• A visible supply path: Seller, fulfilling company, invoice source, and product documentation come with every order, so your purchasing records stand up to an audit.
• Supply work in one place: Portrait brings sourcing, ordering, and inventory visibility into one system, with no revenue share and no long-term contracts.

Your exact savings depend on the products you buy and how much you order. See what your practice would save: get a custom supply-savings breakdown built on your own product mix.

Frequently Asked Questions About 503A and 503B Pharmacies

Can a Practice Buy Compounded Medication Without a Patient-Specific Prescription?

Yes, when an eligible compounded product is supplied for office use by a qualified 503B outsourcing facility and the order meets applicable federal and state requirements. A 503A pharmacy generally compounds for an identified patient with a patient-specific prescription. Confirm the product, facility registration, and state rules before ordering.

Can a 503A Pharmacy Supply Office Stock?

Office-use supply from a 503A pharmacy is generally restricted under federal law. State rules and limited exceptions can affect how a particular order is handled, so a practice should not assume that a 503A pharmacy can supply bulk office stock. Ask the pharmacy to explain the legal basis for the order and confirm the requirements with the relevant state board of pharmacy.

Is a 503B Pharmacy Safer Than a 503A Pharmacy?

The labels alone do not establish that one facility type is always safer than the other. They describe different compounding and oversight models. A buyer should choose the source based on the order it needs to place. It should also review the facility's registration or licensure, inspection history, recalls, product records, storage controls, and state requirements.

Are Drugs From a 503B Outsourcing Facility FDA Approved?

No. A 503B outsourcing facility is FDA-registered and must follow cGMP requirements, but its compounded products are not FDA-approved. The FDA does not approve each compounded formulation before marketing. Registration and inspection are important oversight measures, but neither should be described as product approval.

How Do I Verify a 503B Outsourcing Facility?

Search the FDA's registered outsourcing-facility list for the facility's exact legal name, then review its registration status and available inspection or compliance records. Confirm the state licenses required for the facility and delivery location. Match those records to the name on the quote, invoice, label, and shipping documentation.

Savings vary by practice, product mix, and order volume. Figures reflect select products and are not guaranteed.

Medical Review

Patrick Blake, MD, FAAD reviewed this article for medical and regulatory accuracy. He is a board-certified dermatologist, Fellow of the American Academy of Dermatology, and co-founder and Chief Medical Officer at Portrait. His training includes Cleveland Clinic Lerner College of Medicine, research at the National Institutes of Health as a Howard Hughes Medical Institute research scholar, and dermatology residency at UT Southwestern.

Profiles: LinkedIn | Doximity